Back to top
more

Sangamo Therapeutics (SGMO)

(Real Time Quote from BATS)

$0.25 USD

0.25
5,523,525

0.00 (-1.85%)

Updated Apr 9, 2026 09:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Sangamo Therapeutics (SGMO) Could Be Positioned for a Surge

by Zacks Equity Research

Sangamo Therapeutics, Inc. (SGMO) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

    Swarup Gupta headshot

    These 5 Stocks Have Popped More Than 100% Since Trump's Win

    by Swarup Gupta

    With tax cuts close to becoming law, it makes sense to pick stocks that have posted stellar performances since Trump's win.

      Zacks Equity Research

      The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

        Arpita Dutt headshot

        5 Top-Ranked Drug Stocks that are Broker Favorites

        by Arpita Dutt

        With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.

          Zacks Equity Research

          4 Biotech Stocks to Better Your Financial Health This Winter

          by Zacks Equity Research

          The biotech industry shows a solid performance so far this year except for a brief slump in between of late. However, it is a good idea to select stocks from a sector that is fundamentally strong.

            Zacks Equity Research

            Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?

            by Zacks Equity Research

            GW Pharma (GWPH) will report its fiscal fourth-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.

              Zacks Equity Research

              Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher

              by Zacks Equity Research

              Sangamo Therapeutics (SGMO) shares rose nearly 14% in the last trading session, amid huge volumes.

                Sweta Killa headshot

                Best Sector ETF of Q3 and its Top-Performing Stocks

                by Sweta Killa

                Inside the top performing stocks of top U.S.-focused ETF of Q3.

                  Zacks Equity Research

                  The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

                  by Zacks Equity Research

                  The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

                    Zacks Equity Research

                    Why These 4 Biotech Stocks May Not Lose Momentum Soon

                    by Zacks Equity Research

                    The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.